India Immuno-Oncology Drugs Market to Surpass US$ 550 Million by 2028 - Coherent Market Insights

India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) is estimated to be valued at US$ 265 in 2021 and is expected to exhibit a CAGR of 13.1% over the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Key players operating in the market are focusing on receiving launches from regulatory authorities and this is expected to drive the India immuno-oncology drugs market growth over the forecast period.

For instance, in April 2018, F. Hoffmann-La Roche AG, a Switzerland-based multinational healthcare company, launched its monoclonal antibody atezolizumab under the brand name Tecentriq, in India. Tecentriq is a monoclonal antibody indicated for the treatment of metastatic non-small cell lung cancer.

India Immuno-Oncology Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019 in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 260 million cases and 5.2 million deaths due to Coronavirus (COVID-19) were reported up till November 29, 2021 across the globe.

SARS-CoV-2 infection is more susceptible in the patients with cancer, as compared to the individuals without cancer, as the incidence is likely to increase within the advancing age and high prevalence of cancer possibilities with COVID-19.

Moreover, the significant impact was noticed in clinical services even if the center noticed more than 70,000 new patients with cancer every year. Although, delaying in treatment of cancer can have major adverse effects such as Heart problems, increased risk of other cancers, Infertility, etc.

Browse 5 Market Data Tables and 20 Figures spread through 162 Pages and in-depth TOC on “India Immuno-Oncology Drugs Market”- Forecast to 2028, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/india-immune-oncology-drugs-market-2631

Key players operating in the market are focusing on adoption of inorganic growth strategies such as mergers, approvals, collaborations, and acquisitions, in order to strengthen their position in the global market. For instance, in June 2018, AstraZeneca Pharma India Limited (AZPIL), headquartered at Bengaluru, Karnataka, received import & market permission for Durvalumab (Imfinzi), which is used in treatment of various cancers by working with individual’s immune system, in India by the Drug Controller General of India (DCGI).

Key Takeaways of the India Immuno-Oncology Drugs Market

• India immuno-oncology drugs market is expected to exhibit a CAGR of 13.1% over the forecast period, owing to the rising launches, and regulatory approvals of products. For instance, in July 2018, Dr. Reddy’s Laboratories, a leading multinational pharmaceutical company based in India, launched Hervycta (Trastuzumab), a biosimilar of Roche's Herceptin in India. It is indicated for the treatment of HER2- positive cancer (early breast cancer, metastatic breast cancer, and metastatic gastric cancer).
• Among drug type, immune checkpoint inhibitors segment is expected to account for the largest market share during the forecast period, owing to the research and development by leading manufacturers such as Bristol Myers Squibb, a global biopharmaceutical company, (with their existing drugs) to expand disease indications and development of combination therapies for cancer
• Major players operating in the India immuno-oncology drugs market include Amgen Inc., F. Hoffmann-La Roche AG., Intas Pharmaceuticals Ltd., AstraZeneca plc, Mylan N.V., Dr. Reddy's Laboratories, Bristol - Myers Squibb, Merck & Co., Inc., BIOCAD-Biotechnology Company, Reliance Life Sciences, Biocon Limited, and Hetero Drugs Limited